Introduction {#sec1-1}
============

Estrogen is one of the crucial hormones participating in the proliferation and carcinogenesis of the prostate glands. Genetic polymorphisms of estrogen receptor alpha (*ESR1*) gene in the estrogen metabolism pathway might be involved in the risk of prostate carcinoma development.\[[@ref1]\] Estrogens exert their effects via cognate receptors, *ESR1* and ER beta. Both receptors are located in the prostate glands and they have been postulated to have important effects on these glands.\[[@ref1][@ref2]\]

Catechol-O-methyltransferase (*COMT*) is an important enzyme involved in estrogen metabolism.\[[@ref3]\] Estrogens are catabolized by hydroxylation reactions and 16-hydroxy, 2-hydroxy and 4-hydroxy compounds are inactivated by *COMT*. These catechol estrogen metabolites induced prostate carcinoma in noble rats.\[[@ref4][@ref5]\] Polymorphisms in the genes *ESR1* and *COMT* are associated with the risk of developing other sex steroid hormone-related carcinomas, such as breast carcinoma\[[@ref1][@ref3][@ref6][@ref7]\] endometrial carcinoma\[[@ref7][@ref8]\] and ovarian carcinoma.\[[@ref4][@ref5][@ref8][@ref9]\]

Family history is one of the important risk factors for prostate carcinoma.\[[@ref1]\] Several susceptibility loci or candidate genes have been reported to explain the genetic susceptibility of prostate carcinoma.\[[@ref1]\] However, these genetic factors explain the susceptibility of a very small percentage of familial/hereditary prostate carcinoma pedigrees. Another approach to understand the genetic susceptibility is to estimate the odds risk for prostate carcinoma by analyzing the SNPs of low-penetrance genes. In the current study, we considered prostate carcinoma cases with a family history of the disease as high-risk cases. We performed a case-control study to determine the relation of the *Pvu*II and *XbaI* polymorphisms of *ESR1*, with the risk of developing familial prostate carcinoma in a Turkish population. We evaluated the association between genetic polymorphisms in estrogen-related enzymes and receptors and the risk of developing familial prostate carcinoma. The aim of this study was to determine whether *ESR1* and *COMT* polymorphisms might be involved in the etiopathogenesis of prostate cancer in a Turkish study population.

Materials and Methods {#sec1-2}
=====================

 {#sec2-1}

### Patients {#sec3-1}

In this study, 34 cases with prostate carcinoma, whose first-degree relatives had prostate carcinoma and 30 healthy age-matched male controls were enrolled. Controls were recruited from out-patient clinics at Cukurova University Hospital. Controls were excluded if they had an abnormal prostate specific antigen level. The genotypes of *ESR1* and *COMT* genes were analyzed.

### Genotyping {#sec3-2}

Cukurova University Hospital Ethics Committee approval and informed consent from patients and controls were obtained before blood samples were drawn. Samples of blood (approximately 7 ml) were collected into Vacutainer tubes containing ethylenediaminetetraacetic acid. Deoxyribonucleic acid (DNA) was extracted from peripheral blood lymphocytes using standard salting out extraction method modified from Miller\'s method.\[[@ref10][@ref11]\] Samples were diluted to10 ng/L and stored at −20°C. Polymerase chain reactions (PCR) were performed in a total reaction volume of 25 μL containing 20 ng of genomic DNA, primers (10 pmol of each forward and reverse primers), 2.5 ml × 10 PCR reaction buffer, deoxynucleotide triphosphates (0.2 mmol/L) and 1 U/L AmpliTaq polymerase. PCR amplification was performed in a GeneAmp 9700 thermal cycler (PE Applied Biosystems). Cycling conditions were 95°C for 10 min for 1 cycle; 96°C for 30 s, 60°C for 30 s and 72°C for 30 s for 35 cycles; and an elongation cycle of 72°C for 10 min.

Genotypes of *ESR1* *Pvu*II and *XbaI* in intron 2 were assessed according to the modified method of Hill *et al*.\[[@ref12]\] The sequences of primers for *ESR1* were; 5-AGG CTG GGC TCA AAC TAC AG-3 for the forward primer and 5-CTC TGG GAG ATG CAG CAG AT-3 for the reverse primer. A, T or C allele of the *Pvu*II polymorphism corresponded to the presence or absence of the *Pvu*II restriction site. An A or G allele of the *XbaI* polymorphism corresponded to the presence or absence of the *XbaI* site.

The genotypes of *COMT* were assessed by the method described by Hamajima *et al*.\[[@ref13]\] This method was used to identify a G-to-A polymorphism at codon 158 of *COMT*. A PCR-based restriction fragment length polymorphism assay was performed to detect the presence of the G → A transition at position 1947 in *COMT* (accession no. Z26491). PCR was used to amplify a 185-bp fragment of genomic DNA containing the polymorphism. Briefly, the primer sequences were; 5'- GGAGCTGGGGGCCTACTGTG-3' for the forward primer and 5'-GGCCCTTTTTCCAGGTCTGACA-3' for the reverse primer.

Statistical analysis were performed using SPSS Inc. Released 2006. SPSS for Windows, Version 15.0. Chicago, SPSS Inc. and the level of statistical significance was accepted as *P* \< 0.05.

Results {#sec1-3}
=======

Among control patients, the *ESR1* *Pvu*II genotypes of C/C, C/T and T/T were observed in 37%, 26% and 37%, respectively, whereas the C/C, C/T and T/T genotypes were observed in 18%, 41% and 41% of case patients, respectively \[[Table 1](#T1){ref-type="table"}\]. Among controls, the *ESR1 XbaI* genotypes of G/G, G/A and A/A were observed in 33%, 37% and 33%, respectively, whereas the G/G, G/A and A/A genotypes were observed in 12%, 47% and 41% of case patients, respectively. The C/C genotype of the *Pvu*II site and G/G genotype of the *XbaI* site in the *ESR1* gene were associated significantly with the risk of developing prostate carcinoma.
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The G/G, G/A and A/A genotypes of the *COMT* gene were observed in 50%, 29% and 21% of control patients and in 53%, 21% and 26% of case patients, respectively. The G/A genotype of the *COMT* gene had a weak tendency toward increased risk \[[Table 2](#T2){ref-type="table"}\].
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Discussion {#sec1-4}
==========

*ESR1* is an important mediator of the hormonal response in estrogen-responsive tissue specimens.\[[@ref14]\] The association between bone mineral density and breast carcinoma with genetic polymorphisms of *ESR1* has been evaluated extensively. Some studies showed an association between low bone mineral density and the A/A and C/C genotypes of *XbaI* and *Pvu*II polymorphisms\[[@ref15]\] whereas other studies did not show a significant association between *ESR1* genotypes and bone mineral density.\[[@ref16]\] Because high estrogen levels were related to high bone mineral density, the association among bone mineral density, *ESR1* polymorphism and breast carcinoma risk were demonstrated.\[[@ref17]\] The relation between *ESR1* polymorphism and prostate carcinoma risk was reported by Modugno *et al*.\[[@ref18]\] In their study, the G/G genotype of the *XbaI* polymorphism and the C/C genotype of the *Pvu*II polymorphism increased the risk of developing prostate carcinoma, but the difference was not statistically significant. In the current study, the C/C genotype of the *Pvu*II polymorphism and the G/G genotype of the *XbaI* polymorphism were associated with the risk of developing prostate carcinoma.

Conclusion {#sec1-5}
==========

Polymorphisms of *ESR1* gene in the estrogen metabolism pathway were associated significantly with familial prostate carcinoma risk. The G/A genotype of the *COMT* gene had a weak tendency toward increased risk. Single nucleotide polymorphisms of low-penetrance genes are targets for understanding the genetic susceptibility of familial prostate carcinoma.
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